Multiple Myeloma
Share What You Have Learned
Use the prepared email and Facebook post to share what you have learned about Multiple Myeloma and ACY-1215 with others.
ACY-1215 Clinical Trials
Acetylon is currently sponsoring multiple clinical trials of ACY-1215. One trial (‘100’ study) is evaluating ACY-1215 when used alone and in combination with Velcade® (bortezomib) and dexamethasone. Another trial (‘101’ study) is evaluating ACY-1215 when used in combination with Revlimid® (lenalidomide) and dexamethasone.
ACY-100 study: A Phase I/II, Open-label, Multicenter Study of ACY-1215 Administered Orally as Monotherapy and in Combination with bortezomib and dexamethasone for the Treatment of Relapsed or Relapsed/Refractory Multiple MyelomaThe ‘100’ study is a three-part study conducted at multiple sites across the US, and is partially funded by the Leukemia & Lymphoma Society. In Phase I (a and b), the maximum tolerated dose of ACY-1215 will be determined, alone and in combination with bortezomib and dexamethason. In Phase II, the efficacy of ACY-1215 will be evaluated in combination with bortezomib and dexamethasone. To find out more about this study please refer to clinicaltrials.gov study NCT 01323751.
Georgia
Winship Cancer Institute, Emory University
Contact:
Cathy Sharp
Phone:
404-778-3811
Email:
Principal (Lead) Investigator:
Massachusetts
Massachusetts General Hospital
Contact:
Chi La
Phone:
617-724-5251
Email:
Principal Investigator:
New York
Mt. Sinai Medical Center
Contact:
Kenneth Lau
Phone:
212-241-7846
Email:
Principal Investigator:
Pennsylvania
University of Pennsylvania
Contact:
Kristy Walsh
Phone:
215-615-4822
Email:
Principal Investigator:
Texas
MD Anderson Cancer Center
Contact:
Martha Anderson, RN
Phone:
713-794-1079
Email:
Principal Investigator:
Wisconsin
Medical College of Wisconsin - Clinical Cancer Center
Contact:
Paulette Jacobs
Phone:
414-805-4594
Email:
Principal Investigator:
|
The ‘101’ study is being conducted at multiple sites across the US. This study will assess the maximum tolerated dose of ACY-1215 in combination with Revlimid (lenalidomide) and dexamethasone. (more sites to follow)
To find out more about this study and to find out where this study is being conducted, please refer to clinicaltrials.gov study NCT 01583283.
Massachusetts
Massachusetts General Hospital
Contact
Theresa Le
Email:
Principal Investigator:
North Carolina
University of North Carolina at Chapel Hill
Contact:
Elizabeth Tita
Phone:
919-843-7657
Email:
Principal Investigator:
Tennessee
Sarah Cannon Research Institute
Contact:
Cindy Farley
Phone:
615-329-7237
Email:
Principal Investigator:
Washington
Fred Hutchinson Cancer Research Center
Contact:
Cari Morin
Phone:
206-667-6238
Email:
Principal Investigator:
|
